CardieX’s subsidiary ATCOR Medical has signed a partnership agreement with Datacubed Health for a new remote trial solution.

The new trial solution will help integrate digital vascular biomarker patient monitoring within the Datacubed Health patient engagement platform.

The partnership will enable both entities to jointly carry out trial monitoring across therapeutic programmes.

Datacubed Health CEO Brett Kleger said: “With our integrated remote trial solution, we can not only improve retention rates but also facilitate greater positive outcomes for patients and clinicians alike.”

As part of the partnership, the companies will use the CONNEQT Pulse vascular biomarker device, which leverages SphygmoCor technology to non-invasively offer advanced arterial health biomarkers.

The device, which is supplied by CardieX’s other subsidiary CONNEQT Health, already secured approval from the US Food and Drug Administration.

It features a fit-for-purpose design that facilitates the tracking of digital biomarkers and sends customised alerts to clinicians if vascular biometrics fall within a critical range at the time of the trial.

Clinicians can also reduce adverse events by integrating this device into a trial.

Customised alerts can be programmed to simultaneously notify the patient, as well as the study clinician by integrating planned digital vascular safety monitoring.

Patients and clinicians have several pathways for integrating Pulse with the Datacubed Health platform.

It allows to keep open communication channels for monitoring patient health and maintaining patient engagement to enhance the retention of trials.   

ATCOR Medical clinical trials partnerships managing director Kimberly Tully said: “We are thrilled to partner with Datacubed Health and expand what is possible to elevate the patient experience and unlock the power of our digital vascular biomarkers as tools to monitor patient safety.”